The Nuclear Stock Everyone's Talking About -- But Almost No One Is Pricing in Its Income Potential

Centrus Energy, one of the few U.S. firms licensed to sell low-enriched uranium and the only publicly listed U.S. producer of HALEU, has transformed from large-scale domestic enrichment to a streamlined reseller and small-scale HALEU contractor after shuttering plants in 2013 and the end of the U.S.-Russia Megatons-to-Megawatts program. Revenue collapsed from $1.86bn in 2012 to $193m in 2018 but more than doubled to $442m by 2024, and the stock has rallied ~500% over the past three years as global nuclear projects restart; analysts forecast 2024–2027 CAGRs of ~7% for revenue and ~2% for EPS, with projected 2026 EPS of $4.01. Management could start paying dividends as cash flow strengthens (a 50% payout of 2026 EPS implies ~0.8% forward yield) and raise payouts if a sustained nuclear “supercycle” materializes, supporting modest investor upside but limited near-term market-moving impact.

Analysis

Market structure: Centrus (LEU) sits on a narrow, high-value niche — licensed U.S. LEU seller and the only public HALEU producer — which gives it asymmetric pricing power for advanced-reactor fuel even if overall LEU volumes remain oligopolistic. Utilities and advanced-reactor OEMs (winners) gain optionality and supply security; commodity-driven uranium miners and import-dependent enrichers (losers) face margin pressure as long-term contracted HALEU premiums emerge. Tight supply of HALEU plus long lead times for enrichment suggest a multi-year structural deficit for HALEU, supporting above-normal spreads versus spot U3O8 and driving differentiated cashflow for Centrus.

Risk assessment: Key tail risks are regulatory (export controls/non-proliferation constraints), operational (enrichment plant commissioning delays >6–12 months), and policy reversals (subsidy/contract cancellations) that could cut projected EPS dramatically; a single multi-year HALEU production failure could halve upside. Short-term (days–weeks) price moves will track contract/newsflow; medium-term (6–18 months) depends on DOE/commercial HALEU awards; long-term (3–7 years) hinges on reactor buildouts and secondary supply entry. Hidden dependency: Centrus’ valuation is levered to government contracting cadence and a concentrated utility customer base — losing one major contract materially shifts FCF.

Trade implications: Tactical direct play: accumulate a 2–3% portfolio long in LEU via stock and staggered buy-on-15% dips over 4–12 weeks; pair this with LEAP calls (expiry 2027–2028) sized 0.5–1% for convex upside while limiting cash. Relative value: long LEU vs short URA (or a basket of spot-focused uranium miners) 2:1 for 6–12 months — Centrus’ HALEU moat should outperform miners if HALEU premiums materialize. Use covered-call overlays on 1–3 month expiries at ~+25% strikes to monetize near-term implied volatility; buy 3–6 month protective puts if position >2% to cap downside at ~30%.

Contrarian angles: The market may be overstating fast dividend conversion — a 50% EPS payout in 2026 implies only ~0.8% yield and is unlikely until HALEU cashflows are stable for multiple years; therefore current growth multiple partially prices a dividend that’s not guaranteed. Historical parallel: uranium bull turns (2006–2007) were followed by supply-response busts once miners ramped; if new global HALEU capacity emerges within 3–5 years, Centrus’ premium could compress. Unintended consequence: rapid commercial HALEU uptake could invite stricter export/regulatory scrutiny, delaying sales and compressing near-term multiples.

Key Decisions for Investors

• Establish a staggered long position in LEU equal to 2–3% of portfolio over 4–12 weeks; add additional 1% if LEU shares drop >15% from entry; target hold 6–24 months and reassess on confirmed DOE/commercial HALEU contract flow.
• Buy LEU LEAP calls expiring 2027–2028 sized 0.5–1% of portfolio as leveraged upside (prefer ~30% OTM if available); cap total option exposure to 1% if risk tolerance low.
• Implement a pair trade: long LEU (2%) vs short URA ETF or top 3 spot-focused uranium miners (1%) for 6–12 months — unwind if Centrus misses HALEU delivery targets by >90 days or U3O8 spot rallies >40% indicating miner fundamentals are dominating.
• If holding LEU stock, sell 1–3 month covered calls at ~+25% strike to monetize IV; deploy 3–6 month protective puts if position >2% to limit drawdown to ~30% until HALEU cashflows are contractually secured.
• Monitor three binary catalysts over next 90–180 days: (1) DOE/commercial HALEU contract awards (positive = double exposure), (2) announced multi-month commissioning delays (negative = reduce to zero), and (3) U.S. policy/subsidy changes for advanced reactors (positive = incremental +50–100% upside potential over 12–36 months).